The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Deloitte; G1 Therapeutics; Gilead Sciences; Macrogenics; Menarini; Novartis; Novartis; Radius Health; Roche; Servier
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium
 
Mafalda Oliveira
Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche
 
Kevin Punie
Honoraria - Gilead Sciences (Inst); Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst)
Research Funding - MSD (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche
 
Valentina Boni
Employment - Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Honoraria - Amunix; Guidepoint Global; IDEAYA Biosciences; Loxo; Puma Biotechnology
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Lilly; SOLTI; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); TESARO (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Ayca Gucalp
Research Funding - BioAtla (Inst); Bristol-Myers Squibb (Inst); Innocrin Pharma (Inst); Merck (Inst); Novartis (Inst); OncoTherapy Science (Inst); Pfizer (Inst); Roche (Inst); Zenith Epigenetics (Inst)
 
Payal D Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Merck (I); Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
 
Maria J. de Miguel
Honoraria - Janssen; MSD; Roche
Consulting or Advisory Role - Syneos Health
Research Funding - Abbvie (Inst); Achilles Therapeutics (Inst); Array BioPharma (Inst); Basilea (Inst); Bayer (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); Faron Pharmaceuticals (Inst); Genentech (Inst); Genmab (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pharmamar (Inst); Regeneron (Inst); Zenith Epigenetics (Inst)
 
Priyanka Sharma
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Genzyme; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Cosmo Biosciences (I); Gilead Sciences; Merck (Inst); Novartis; Novartis (Inst)
Travel, Accommodations, Expenses - Seagen
 
Lisa Bauman
Stock and Other Ownership Interests - Pfizer
 
Eric Campeau
Employment - LQT Therapeutics; Zenith Epigenetics
Stock and Other Ownership Interests - LQT Therapeutics; Zenith Epigenetics
Consulting or Advisory Role - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - Zenith Epigenetics
 
Sarah Attwell
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - Zenith Epigenetics patent for the use of ZEN003694 in prostate cancer
 
Margo Snyder
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Travel, Accommodations, Expenses - Zenith Epigenetics
 
Karen Norek
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
 
Emily Johnson
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
 
Michael H. Silverman
Employment - BioStrategics Consulting
Leadership - BioStrategics Consulting
Stock and Other Ownership Interests - Acurx Pharmaceuticals Inc; Can-Fite BioPharma
Consulting or Advisory Role - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - Acurx Pharmaceuticals Inc
 
Sanjay Lakhotia
Employment - Zenith Epigenetics
Leadership - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Travel, Accommodations, Expenses - Zenith Epigenetics
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Jennifer Keating Litton
Honoraria - UpToDate
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Medivation/Pfizer; Pfizer
Speakers' Bureau - Clinical Care Options; Med Learning Group; Medpage; Medscape; Physicans' Education Resource; Prime Oncology; UpToDate
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Travel, Accommodations, Expenses - Clinical Care Options; Med Learning Group; Medscape; Physicans' Education Resource
Other Relationship - Medivation/Pfizer
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst)
Other Relationship - Clinical Care Options; Clinical Education Alliance; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals